From the Research Laboratories of Schering AG, 13342 Berlin, Germany; and ¶ Protein Chemistry Group, Max-Delbrück-Center for Molecular Medicine, 13092 Berlin, Germany
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Breast tumors as well as breast cancer cell lines have the capability to adapt to the prevailing concentration of antiestrogen, resulting in resistance to the drug. The mechanisms that lead to antiestrogen-resistance in breast cancer patients as well as in cell culture model systems are still poorly understood to date (7).
Therefore, we established an antiestrogen-resistant breast cancer cell line as an in vitro model system in order to analyze differentially expressed genes and proteins. To this end, the human ER-positive breast carcinoma cell line T47D, which is growth-stimulated by 17ß-estradiol (E2) and sensitive to antiestrogens, was exposed to the pure antiestrogen ZM 182780 at a concentration of 10-6 M over a period of several months. From this treatment, a ZM 182780-resistant cell line evolved which was called T47D-r (8). We demonstrated that T47D-r cells have lost expression of the ER
and show an up-regulation of the epidermal growth factor receptor and c-erb B2, supporting the notion that cross-talk exists between ER
and growth factor signaling pathways (8).
The screening of global mRNA changes by hybridization of RNA to either cDNA or oligonucleotide arrays in a high-throughput manner has only become possible in recent years (9) and has been applied to the analysis of gene expression profiles of different breast cancer cell lines, to the study of the response of breast cancer cells to E2, to the molecular profiling of breast cancer biopsies in relation to the ER status, and to the successful subclassification of human breast tumors (1015).
Proteomics is a complementary tool to mRNA analysis for assessing global changes in cellular protein expression and it can provide additional insight into post-translational modifications of proteins. Recent progress in the field of proteomics has resulted in publications on proteomes for normal and tumor-derived breast cancer cell lines and breast cancer biopsies, and results have been reviewed and discussed (1621). Two-dimensional (2D) gel electrophoresis coupled with mass spectrometry (MS) identification of proteins has for example been carried out for establishing a catalogue of proteins that are expressed in human tumorigenic and nontumorigenic breast cell lines (2227). Although cultivated cells tend to have a lower complexity of expressed proteins than human biopsies, comparison of only distantly related or rather unrelated cellular systems resulted in a large number of differentially expressed proteins, however with limited clinical relevance. The proteomics studies of normal human breast, premalignant lesions, and breast cancer biopsies generated data with stronger clinical impact, but even higher biological complexity (2832). Moreover, in specialized approaches, luminal and myoepithelial breast cells from reduction mammoplasties were analyzed by proteomics after a double antibody magnetic sorting technique (33), and membrane proteins of breast cancer cell lines were studied after cell fractionation (34). This lowered the complexity of the systems and increased the number of low-abundance proteins that could be detected. Recently, a proteomics study of the human breast cancer cell line MCF-7 with or without treatment of the anti-tumor drug doxorubicin has been reported (35).
Today, only a limited number of studies have been published in which both technologies, proteomics and mRNA expression profiling, have been compared using the same samples (3638). There are reports that absolute protein and mRNA expression levels do not correlate well when total expression profiles are analyzed (39). With regard to a comparison of those genes and proteins that are differentially expressed, several studies have been published recently (4047). The conclusion drawn by the authors on the correlation of differential RNA and protein expression varies between moderate and no correlation and seems to depend at least partially on the abundance of the mRNA or the protein under investigation.
The aim of the present study was to define and compare differential gene and protein expression in a model system of antiestrogen-sensitive and -resistant breast cancer and to evaluate concordance of mRNA and protein data. It is expected that a more detailed analysis of these changes will give new hints about the mechanisms that lead to the development of antiestrogen-resistant breast cancer and may eventually help to propose novel strategies and targets for an effective breast cancer therapy.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cell Culture
The human breast cancer cell line T47D was obtained from the American Type Cell Culture Collection (Manassas, VA). The cells were routinely grown in phenol red-free RPMI 1640 medium (Biochrom, Berlin, Germany) supplemented with 10% fetal calf serum (LifeTechnologies, Karlsruhe, Germany), 2 mM glutamine (LifeTechnologies), 200 mU/ml insulin (Sigma, Deisenhofen, Germany), and 10-10 M E2. The parental cells were cultivated in parallel to the antiestrogen-resistant cells. Prior to experiments, the cells were exposed to standard medium: phenol red-free RPMI 1640 medium, supplemented with 10% charcoal-treated fetal calf serum, 2 mM glutamine, and 10-10 M E2. The antiestrogen-resistant cells were grown continuously in standard medium with 10-6 M ZM 182780. Cells were grown at 37 °C in a humidified atmosphere with 5% CO2. For generation of protein extracts, 8 x 106 T47D cells were seeded in standard medium and T47D-r in standard medium plus 10-6 M ZM 182780 (day 0). On day 3, medium was replaced for 24 h with standard medium in the case of T47D and standard medium plus 10-7 M ZM 182780 in the case of T47D-r. Cell cultures that had reached 70% confluence were harvested on day 4.
For isolation of RNA, T47D were cultivated in standard medium and T47D-r in standard medium plus 10-7 M ZM 182780 for 24 h. Poly(A)+ RNA from two independent cell culture experiments was hybridized to the HuGeneFL array, and total RNA from a further independent cell culture experiment was hybridized to the Hu95A array.
Proliferation Assay
The proliferation rates of ZM 182780-sensitive T47D and ZM 182780-resistant T47D-r were measured with the 4,5-[dimethylthiazol-2-yl]-2,5-diphenyltetrazolium (MTT) assay. Cells grown to 7080% confluence were harvested and seeded in 200 µl in 96-well microtiter plates at 2500 cells/well in phenol red-free RPMI 1640, 2 mM glutamine, 10% charcoal-treated fetal calf serum (day 0). E2 (10-10 M), or the vehicle control ethanol at 0.001%, or E2 (10-10 M) plus ZM 182780 at concentrations of 10-10 to 10-6 M were added. Mitochondrial activity was measured on day 7 after plating by adding 20 µl MTT reagent (Sigma, 5 mg/ml in PBS) for 35 h at 37 °C to the medium. Afterward, the supernatant was removed and the formazan crystals were dissolved in dimethylsulfoxide. Absorbance was measured at 550 nm. Experiments were performed at least twice and one representative experiment with mean from 6 wells is shown.
Generation of Protein Extracts for Proteomics Analysis
For sample preparation, 1 x 1071 x 108 cells were washed three times with PBS without Ca2+, Mg2+ to remove serum proteins and detached by treatment with PBS (Ca2+, Mg2+) containing 2 mM EDTA. The pelleted cells were resuspended in PBS containing a protease inhibitor mixture (CompleteTM Mini EDTA-free, pepstatin, and phosphoramidon) (all from Roche, Mannheim, Germany) and sodium-orthovanadate (Sigma) and stored in aliquots as dry pellets at -80 °C before use. Cell pellets were resuspended in 20 mM Tris/HCl, pH 8.0, 2 mM MgCl2 containing protease inhibitor mixture and sodium-orthovanadate and lysed at 4 °C with ultrasound (Sonorex RK31; Bandelin, Berlin, Germany) in the presence of glass beads of 1.72.0 mm diameter (Roth, Karlsruhe, Germany). The DNA in the lysate was digested with benzonase (Merck, Darmstadt, Germany) at room temperature for 30 min.
Afterward, lysis buffer was added containing 7 M urea (Amersham Biosciences, Uppsala, Sweden), 2 M thiourea (Merck), 1% (w/v) dithiothreitol (Sigma), 2% (w/v) 3-((3-cholamidopropyl)dimethylammonio)-1-propane sulfonate (Electrophoresis Reagent; Sigma) and 0.51% immobilized pH gradient (IPG) buffer (Amersham Biosciences), corresponding to the pH gradient. The lysate was vortexed for 1 min and centrifuged. The protein concentration was determined in the supernatant with the modified Bio-Rad protein assay kit (Bio-Rad, Hemel Hempstead, UK) and was 35 µg/µl.
2D-SDS-PAGE
Samples were loaded onto IPG strips (Immobiline DryStrips; Amersham Biosciences) using 100 µg total protein for analytical gels, which were silver-stained, and 1500 µg total protein for preparative gels, which were stained with colloidal Coomassie brilliant blue G250 (Serva, Heidelberg, Germany). For the analytical gels, it was taken care that the amount of protein loaded onto the IPG strips was within the linear range of the silver stain detection. Spots that were saturated have not been included in the analysis. Isoelectric focusing was performed on an IPGphor unit (Amersham Biosciences) for IPG gradients pH 310, pH 58 (Bio-Rad), and pH 47 and on a Multiphor unit (Amersham Biosciences) for IPG gradients pH 611.
For the second-dimension SDS-PAGE using the Hoefer ISO-DALT system (Amersham Biosciences), focused Immobiline DryStrips were equilibrated in SDS buffer and transferred onto the surface of 13% T/2.6% C polyacrylamide/bisacrylamide gels (AppliChem, Darmstadt, Germany) and embedded in 1% agarose (Amersham Biosciences) containing traces of bromophenol blue (Amersham Biosciences). Gels were run in SDS-PAGE running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) at 20 °C until the dye-front reached the end of the gel. All samples were run at least in duplicates from three independent cell culture experiments leading to 12 gels for each pH gradient, which were compared.
Image Analysis
Analytical gels were scanned on an UMAX Mirage II scanner (UMAX Systems, Düsseldorf, Germany) at 300 dpi with 12-bit gray scale levels in tagged image file format (TIFF), and images were analyzed using the Phoretix-2D advanced software V 5.1 (Nonlinear Dynamics Limited, Newcastle upon Tyne, UK). All gels in the analyses were scanned with identical parameters. In order to perform differential analysis of the 2D gels with the Phoretix-2D advanced software, the individual spots of each gel were detected by their boundaries, and the spot volume corresponding to the protein abundance was calculated automatically. Spot detection was performed with automatic splitting and features resulting from nonprotein sources (e.g. dust particles and scratches) were filtered out. Manual editing of the gels was necessary especially in the higher molecular weight region. The background was subtracted using the mode-of-nonspot function. With the image warping function user seeds were set on the gels for more accurate image superimposition. Spot matching was performed using T47D gel images as reference. Total spot volume normalization was used for accurate comparison of the different images. Only protein spots that were reproducibly different in all three experiments by at least a factor of two were considered to be differentially regulated and were excised from preparative gels for identification.
Protein Identification
Spots excised from Coomassie-stained preparative gels were destained by washing first with digestion buffer (25 mM ammonium bicarbonate) and then with 50% acetonitrile/digestion buffer. These steps were repeated three times. Afterward, the gel pieces were dehydrated with acetonitrile and dried under vacuum in a SpeedVac concentrator. Digestion was performed with sequencing grade trypsin (Promega, Madison, WI). A volume of 12 µl of a solution containing 20 ng/µl trypsin in digestion buffer was added to each of the gel pieces. After 30 min of proteolysis at 37 °C, 10 µl digestion buffer was added and digestion was continued overnight. The supernatant was concentrated and desalted on ZipTips (Millipore, Bedford, MA) according to the manufacturers instructions.
For matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) and MALDI post-source decay analysis, the peptides were eluted with 1 µl 50% acetonitrile/0.1% trifluoracetic acid onto the MALDI target. One microliter of a saturated -cyano-4-hydroxycinnamic acid solution in 70% acetonitrile/0.1% trifluoracetic acid was added to each sample. Spectra were acquired on a Voyager-DE STR (Perseptive Biosystems, Framingham, MA). For nano-electrospray ionization tandem MS analysis, the peptides were eluted from the ZipTips with 3 µl 50% acetonitrile/1% formic acid. The spectra were recorded on a quadrupole-TOF (Micromass, Manchester, UK) equipped with a nanoflow Z-spray ion source. The peptide mass fingerprints and tandem MS spectra obtained were analyzed searching the NCBI nonredundant (NCBI nr) Protein Data Base, the translated, assembled expressed sequence tags (ESTs) in the LifeSeqGold templates database (Incyte, trLGtemplates), and the nonredundant EST division of the GenBank, EMBL, and DDBJ databases with the ProFound (prowl.rockefeller.edu/cgi-bin/ProFound) or Mascot (www.matrixscience.com) software.
Western Blot Analysis
The cells were lysed on ice in lysis buffer containing 10 mM Tris/HCl, pH 7.5, 50 mM NaCl, 5 mM EDTA, 30 mM sodium-pyrophosphate, 50 mM NaF, 1 mM phenylmethylsulfonyl fluoride (Sigma), and the protease inhibitor mixture CompleteTM Mini (Roche), phosphatase inhibitor cocktail I and II (Sigma), and 1% (w/v) Triton X-100 (Sigma). The plates were left on ice for 10 min, and the lysates were transferred to Eppendorf tubes. The lysate was vortexed 2 x 30 s and cellular debris was pelleted at 14,000 rpm for 20 min at 4 °C. The supernatant was frozen at -80 °C. Protein concentration of the cell lysate was determined with the DC Protein Assay Kit II (Bio-Rad). Equal amounts of protein were separated on 10% bis-Tris gels (NuPAGE®; Invitrogen, Karlsruhe, Germany) and blotted to Optitran BA-S 85 reinforced nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) by semi-dry blotting in cathode buffer (25 mM Tris base, 40 mM 6-amino hexane acid, 20% methanol), anode I buffer (30 mM Tris base, 20% methanol), and anode II buffer (300 mM Tris base, 20% methanol) at 0.8 mA/cm2 for 60 min. The membrane was incubated in blocking buffer, i.e. Roti®-Block (Carl Roth GmbH, Karlsruhe, Germany) for 90 min at room temperature. Incubation with the primary antibodies was carried out in blocking buffer at 4 °C overnight. The mouse monoclonal -cathepsin D antibody Ab-1 (clone BC011) was purchased from OncogeneTM Research Products (Boston, MA), and
-ß-actin was a rabbit polyclonal serum purchased from Sigma. As secondary antibodies
-mouse and
-rabbit horseradish peroxidase-coupled antibodies (Amersham Biosciences) were used. The
-cathepsin D antibody was diluted 1:500, and the
-ß-actin serum 1:1000 in blocking buffer. Afterward, membranes were washed 3 x 5 min in PBS-T (PBS with 0.1% Tween-20) and incubated with the respective secondary horseradish peroxidase-coupled antibody (diluted 1:2000) for 1 h at room temperature. Membranes were again washed 3 x 5 min in PBS-T. Detection was carried out with the ECL Plus system (Amersham Biosciences) according to manufacturers instructions. Blots were quantitated with the ImageMaster TotalLab 2.0 software (Amersham Biosciences).
Affymetrix DNA Chip Hybridization
One to 2 µg of poly(A)+ RNA or 10 µg of total RNA were converted into double-stranded cDNA using a modified oligo-dT primer including a 5' T7 RNA polymerase promoter sequence and the Superscript Choice system for cDNA synthesis (Life Technologies, Rockville, MD). In vitro transcription was performed with T7 RNA polymerase (T7 Megascript kit; Ambion, Austin, TX) and 0.51 µg of double-stranded cDNA template in the presence of a mixture of ATP, CTP, GTP, biotin-11-CTP, and biotin-16-UTP (ENZO Diagnostics, Farmingdale, NY). Twenty micrograms of cRNA were fragmented randomly by incubating in 40 mM Tris acetate, pH 8.1, 100 mM K+ acetate, and 30 mM Mg2+ acetate at 94 °C for 35 min. The Affymetrix HuGeneFL array and the Hu95A array were hybridized, washed, and stained according to standard protocols. The arrays were scanned with a confocal scanner from Affymetrix. The hybridization intensities on the different chips were analyzed by an in-house-developed software.
Affymetrix arrays were normalized using the Maximum Order Preserving Set method. This method identifies a subset of genes that do not change their expression between two experiments. The intensity scatter plot for all genes from this restricted set is approximated by a nonlinear regression function that is then used for normalization. In a first step, all arrays are sorted by their intensity (median of all individual oligonucleotide signal intensities). The experiment with the median intensity of all arrays is chosen as the reference experiment. Each of the remaining arrays is normalized separately against the reference experiment. For each such pair-wise normalization, all genes that are present on both arrays are identified. A gene is considered present if the p value for a one-sided matched-pairs signed-rank Wilcoxon test applied to all unmasked perfect match (PM) versus mismatch (MM) oligonucleotide signal intensities is below 0.04. To identify a set of oligo probe pairs belonging to genes with unchanged expression, all probe pairs for genes present on both arrays are sorted by their intensity differences of perfect match minus mismatch oligonucleotide (PM-MM) and are assigned the corresponding ranks. That is, each probe pair has a rank on the reference array and a usually different rank on the array to be normalized. Now, an iterative process is used to remove probe pairs with high rank jumps between the two experiments until a subset of probe pairs with identical ranks on both arrays is obtained (maximum order preserving set). The assumption is that probe pairs with high rank jumps belong to genes that do change their expression, whereas probe sets with small rank jumps belong to genes with constant expression. For all probe pairs from the order preserving set, the intensity difference PM-MM on the reference array is plotted against PM-MM on the array to be normalized and the best-fitting forth order polynomial with no zero-order term is identified. In a last step, all PM-MM differences from the array to be normalized are transformed by the thus identified nonlinear function. In case of the HuGeneFL array, where two independent hybridization experiments have been performed, the average expression change between the replica experiments had to be at least 2-fold to be considered as regulated.
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
|
|
|
|
|
|
|
|
However, the strength of differential expression can vary. For 11 proteins the corresponding mRNAs are not well defined, i.e. either only one differential expression value is available and the fold-change is below 2 or the fold change is weak and not consistent between the experiments. Eight proteins were inversely regulated on the protein compared with the mRNA level. The differential expression of these mRNAs was often below 1.8-fold (Table II), whereas in standard Affymetrix experiments only genes regulated by a factor of two and higher are considered for subsequent studies.
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|
To extend previous studies, it was our aim to analyze differential gene expression on both the mRNA level by Affymetrix DNA chip hybridization and on the protein level by proteomics. In addition, we expected to achieve a better insight into the changes that accompany the development of antiestrogen-resistance in our system.
Affymetrix DNA chip hybridizations were carried out on the commercially available HuGeneFL and Hu95A array. In sum, a total of 10,919 nonredundant genes and ESTs were analyzed on the two arrays. A total of 266 genes (2.4%) were found to be up-regulated and 300 (2.7%) down-regulated more than 2-fold in T47D-r compared with T47D (Table I).
Compared with the proteomics analysis, where only 84 differentially regulated spots were identified on 2D gels, far more genes were found to be differentially expressed. This can be explained by mRNA measurements having on the one hand a higher degree of sensitivity and the capability to detect also weakly expressed mRNAs and on the other hand oligonucleotides arrayed in parallel allowing for a higher degree of automation and throughput.
When the total cellular protein content from three independent cell culture experiments of T47D and T47D-r was analyzed, 84 spots were found to be reproducibly variant more than 2-fold. Sixty-six proteins were identified corresponding to 47 distinct proteins because 11 proteins were present in more than one spot on the gel. The fact that one protein is localized in two different spots on the gel can be explained by post-translational modifications, e.g. phosphorylation, glycosylation, or limited proteolytic cleavage (48, 49).
Three proteins (stathmin/oncoprotein 18, 14-3-3 , and Nudix hydrolase NUDT5) were identified from two or three independent spots on the gel and were regulated both up in one spot and down in another in T47D-r compared with T47D (Fig. 5). The regulation in different directions in separate spots could also be the result of post-translational modifications. For instance, for 14-3-3
and stathmin signal-induced phosphorylation has been described (50, 51). These three distinct proteins were excluded from the comparison with the Affymetrix results because their total amount was not investigated in this experimental setup. Another six proteins, which were not present on the two arrays hybridized, were also not included in the comparison with the Affymetrix results (Fig. 5).
The comparison of differential mRNA with protein expression data revealed that 19 out of 38 distinct proteins were up- or down-regulated in parallel at the mRNA and protein level, i.e. there is a concordance for the direction of changes on mRNA transcript and protein expression level for 50% of the distinct proteins for which a probe set was present on the two arrays.
In 11 cases, the differential expression level was not well-defined, therefore no comparison between protein and mRNA regulation could be made. For eight proteins, an inverse regulation on protein versus mRNA level was observed. This inconsistency between differential mRNA transcript and protein expression levels in a steady-state system, i.e. antiestrogen-sensitive and antiestrogen-resistant human breast cancer cells, as investigated here could be due to the presence of regulatory influences that are currently not understood (52). All explanations taken into account would require that mechanisms as detailed below have to work differentially between the parental cell and its antiestrogen-resistant derivative. In case the protein is up-regulated and mRNA is unchanged or down-regulated, one could postulate that either this particular protein is translated with higher efficiency, or it has a longer half-life, or that due to post-translational modification the protein appears de novo in an independent spot. When the protein is down-regulated while the mRNA is unchanged or up-regulated, the protein could have a shorter half-life, or it is translated with a lower efficiency. Further possibilities are that post-translational modification mechanism are turned off or that the protein is degraded into products no longer detectable because of various technical reasons (e.g. molecular weight or detection limit) leading to disappearance or decreasing intensity of this particular spot.
Because only those spots were considered to be differentially expressed in the proteomics analysis that were regulated by a factor of two or more, it is conceivable that a given protein is present in further spots for reasons described above but was not detected as being regulated or expressed below the detection limit. If the identity of all further possible isoforms of a protein has not been analyzed completely, this may influence the correlation between mRNA and protein and represents a limitation. In addition, when one looks in detail at the fold regulation on the mRNA level these factors are often below 1.8. In a standard gene expression analysis, only mRNAs with factors 2-fold are considered for subsequent analyses. A comparison of individual protein quantities from 2D gels with mRNA expression data has therefore to be performed with caution.
Biological Interpretation of the Data
In order to investigate the identified proteins further, we sorted them according to their functional category (Table III). Several of them are housekeeping enzymes, mitochondrial proteins, or involved in protein degradation. However, we also found proteins that play a role in signaling pathways or whose function is currently unknown. For several proteins that were identified in the proteomics analysis and by DNA chip hybridization, their role in regard to regulation by E2 and endocrine resistance will be depicted.
The protease cathepsin D was down-regulated on the protein and mRNA level in T47D-r compared with T47D. The protein was found at six different locations at the same apparent molecular mass (33 kDa) but different isoelectric points (between pH 5 and 6.5) on the 2D gels (Fig. 4). The different locations indicate that isoforms of cathepsin D exist. Cathepsin D is synthesized as pre-proenzyme that is post-translationally phosphorylated (53, 54). The 52-kDa pro-cathepsin D is cleaved to the enzymatically active 48-kDa heterodimer consisting of a 14- and 34-kDa subunit, and only the latter was identified in this proteomics study. The fold change on the protein level varied for the six spots between undetectable in T47D-r compared with T47D and down-regulated 22.9- to 2.1-fold (Table II). In the Western blot analysis, the cathepsin D form of 32 kDa was down-regulated 2.4-fold in T47D-r compared with T47D (Fig. 6).
On the mRNA level cathepsin D was down-regulated by a factor of more than 7.5- and 4.3-fold on the HuGeneFL array in T47D-r compared with T47D in the first and second cell culture experiment, respectively, and in the third experiment on the Hu95A array cathepsin D was down-regulated 7.3-fold.
Already in an early proteomics study on breast cancer cell lines a secreted 46-kDa protein was identified that was induced by E2 in several human ER-positive cell lines and later determined by specific antibodies to be the protease cathepsin D (55). Thus, the cathepsin D gene is a well-known E2-regulated gene, and induction by E2 has been demonstrated for the ER
-positive breast cancer cell lines T47D, ZR-75-1, and MCF-7 (56, 57). Because T47D-r cells have lost expression of ER
, the E2-induction of cathepsin D is abrogated when compared with T47D cells. Differential expression of cathepsin D was found in both human breast cancer cell lines, breast biopsies, and reduction mammoplasties (33, 35).
The small GTPase Rab11a was down-regulated in T47D-r compared with T47D on the protein and mRNA level. On the protein level, Rab11a was found to be decreased 6.6-fold in T47D-r versus T47D. In the HuGeneFL and Hu95A array hybridization experiments, Rab11a was down-regulated by a factor of 1.8, 2.8, and 2.3 in mRNA from three independent cell culture experiments. Rab11a belongs to the large family of Ras-related small GTP-binding proteins that are involved in the regulation of vesicular transport along the endocytotic and exocytotic pathway (58, 59). It has been shown that Rab11a is regulated by E2 in the human endometrial cell line Ishikawa after transfection with either ER or ß, whereas treatment with ZM 182780 inhibited the E2-dependent induction of Rab11a (60). The fact that Rab11a is down-regulated on the protein and mRNA level in the breast carcinoma cell line T47D-r, which is continuously treated with ZM 182780 and has lost ER
expression, indicates that also in this cell line expression of Rab11a might at least be partially under the control of the ER. Interestingly, the Rab11a protein was recently found to be up-regulated in matched pairs of microdissected ductal carcinoma in situ compared with normal ductal breast tissue by an extensive 2D-PAGE-based proteomics analysis, and results were confirmed by immunohistochemical staining (32).
Another GTPase, the MxA protein, was identified from two spots in T47D-r. Comparing the spot intensities, the up-regulation was found to be 2- and 5.6-fold in T47D-r versus T47D, respectively. On the mRNA level, MxA was strongly up-regulated by more than 8.7-, 5.2-, and 3.6-fold in T47D-r versus T47D in the first, second, and third chip hybridization experiment on the HuGeneFL and Hu95A arrays, respectively. MxA, which belongs to the dynamin family of GTPases (61), is induced by interferon and ß, and the promoter contains two functional interferon response elements (6264). One could assume that the transcription factors STAT1 and STAT2, which bind to interferon response elements (65), are involved in the up-regulation of MxA. Thus the up-regulation seen for MxA in T47D-r can potentially be explained by an activated STAT pathway in these cells.
hAG-2, which is the human homologue of the Xenopus laevis anterior gradient 2 protein (gene symbol AGR2), was down-regulated on the protein and mRNA level in T47D-r. The fold regulation on the mRNA level was 5.3-fold on the Hu95A array. On the protein level, hAG-2 is decreased by a factor of 2.9 in T47D-r compared with T47D. On the mRNA level, hAG-2 has been shown to be co-expressed with the ER in breast cancer cell lines (66). As the T47D-r cells have lost protein and mRNA expression of the ER (8), the identification of hAG-2 protein in the ER-positive T47D cells confirms the results shown previously on the mRNA level. Although the function of hAG-2 in the mammalian system is unknown, based on the expression data it was proposed that hAG-2 might be involved in the tumor cell biology of hormone-responsive, well-differentiated breast cancer (66).
In a proteomics study in which the plasma membranes of several ER and epidermal growth factor receptor-positive human breast cancer cell lines were enriched, the hAG-2 homologous protein hAG-3 was identified (34), and in a focused follow-up study, hAG-2 and hAG-3 were analyzed by immunohistochemical methods (67). Here, it was demonstrated by quantitative reverse transcriptase PCR and immunohistochemistry on tissue microarrays that hAG-2 expression correlated positively with ER and negatively with epidermal growth factor receptor expression (67). Bioinformatic analysis indicated that the hAG-2 promoter contains four putative estrogen response elements. In a yeast 2-hybrid screen, hAG-2 was shown to interact with
-dystroglycan (DAG-1) and glycosylphosphatidylinositol-anchored protein C4.4a (67), and it was suggested that hAG-2 as secreted protein interacts with the extracellular matrix.
Many other proteins were found to be variant in our model system, which have not yet been described in association with the development of breast cancer and which are now further investigated to understand their role in endocrine-resistant breast cancer.
Conclusion
In the present study, we identified and compared differentially expressed genes and proteins in a model system of antiestrogen-sensitive and -resistant breast cancer and evaluated consistency between mRNA and protein data. In our steady-state model, concordance was 50%. By combining proteomics and Affymetrix technologies, we achieved a more detailed insight into the expression changes that accompany the development of antiestrogen-resistance in an in vitro system. RNA expression profiling on Affymetrix oligonucleotide arrays is a complementary method to proteomics as gel-based proteomics is often unable to detect the low-abundance proteins. Several known E2-regulated genes like cathepsin D or genes co-expressed with the ER and likely also E2-regulated like hAG-2 are expressed in the parental T47D cell line. As manifestation of the antiestrogen-resistant phenotype of the T47D-r cells cathepsin D and hAG-2 are down-regulated on the RNA and protein level. The discovery of gene and protein expression changes in the context of antiestrogen resistance may allow for a better understanding of the mechanisms that lead to endocrine-resistant breast carcinoma.
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
FOOTNOTES |
---|
Published, MCP Papers in Press, October 12, 2003, DOI 10.1074/mcp.M300047-MCP200
1 The abbreviations used are: ER, estrogen receptor; 2D, two-dimensional; E2, 17ß-estradiol; EST, expressed sequence tag; IPG, immobilized pH gradient; MALDI, matrix-assisted laser desorption/ionization; MS, mass spectrometry; MTT, 4,5-[dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide; TOF, time-of-flight.
2 A. Sommer, personal communication.
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
M. H. and I. B. contributed equally to this article
|| To whom correspondence should be addressed: Schering AG, Enabling Technologies, 13342 Berlin, Germany. Tel.: +49-30-468-17974; Fax: +49-30-468-16707; E-mail: anette.sommer{at}schering.de
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() |
---|